Fig. 5: Mutations associated with survival and cumulative incidence of relapse in the pediatric cohort.
From: Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age
A The overall survival for pediatric patients with SNV/indels in TP53 was significantly inferior to patients with TP53 wild-type (Kaplan–Meier survival estimation, log-rank test). B TP53mut cases also showed an increased risk of relapse (cumulative incidence, Gray’s test20, no adjustments for multiple comparisons in this descriptive context). C Mutations in PCBP1 show a tendency toward prognostic relevance. D Cases with lymphomas harboring MYC and PCBP1 mutations are characterized by an increased risk of relapse. Gains or amplifications on 13q31 specific to GPC5/MIR17HG were significantly associated with a higher risk of relapse (E). The lowest incidence of relapse (0/38 cases) was observed for the TP53wt sub-group and mutations in FBXO11/FOXO1 (F).
